Skip to main content

Table 4 Association between NAT2-imputed phenotype, CYP1A1 and CYP1A2 genotype, and prostate cancer

From: Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan

  Cases Controls P OR (95% CI)a
NAT2-imputed phenotype
 Rapid acetylator 206 212   1.00
 Intermediate acetylator 118 121 0.69 1.05 (0.83–1.32)
 Slow acetylator 27 18 0.034 1.65 (1.04–2.61)
CYP1A1
 AA 207 232   1.00
 GA 119 105 0.12 1.20 (0.95–1.52)
 GG 25 14 0.023 1.76 (1.08–2.87)
 GA + GG 144 119 0.034 1.27 (1.02–1.59)
CYP1A2
 CC 34 47   1.00
 CA 177 171 0.045 1.43 (1.01–2.03)
 AA 140 133 0.048 1.44 (1.00–2.06)
 CA + AA 317 304 0.035 1.43 (1.03–2.00)
  1. BMI body mass index, OR odds ratio, CI confidence interval
  2. aOR (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake